Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KvLQT1 (also known as Kv7.1) is a voltage-gated potassium channel subunit encoded by the KCNQ1 gene. It is a key component of the IKs channel complex in cardiac tissue, responsible for the slow delayed rectifier potassium current. Mutations in KCNQ1 can lead to Long QT syndrome type 1 (LQT1) and deafness. The channel is modulated by KCNE subunits and phosphorylation, affecting cardiac repolarization and epithelial ion transport.
Blockade of KvLQT1 currents, Modulation of cAMP responses
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium Voltage-Gated Channel Subfamily Q Member 1 (KvLQT1).